Dr Matteo Carlino

Clinical Senior Lecturer
Medicine: Westmead Clinical School


Map

Selected grants

2018

  • Epigenetic targeting of T cell dysfunction ("exhaustion") in patients failing treatment with immune checkpoint inhibitors; Hersey P, McGuire H, Shklovskaya E, Gallagher S, Carlino M; Cancer Council New South Wales/Research Grant.
  • A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP); Atkinson V, Atkinson V, Carlino M, King M, Lo S; National Health and Medical Research Council (NHMRC)/Project Grants.

2017

  • Obstructive sleep apnoea in cancer cohorts: interactions with cancer biology; Kairaitis K, French J, Amis T, deFazio A, Brand A, Mann G, Howle J, Carlino M, Wong E, Clarke C, Elder E; ResMed Foundation/Research Grant.

2015

  • Significance of soluble PD-L1 in melanoma patients; Carlino M; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Determining the mechanisms of MEK inhibitor resistance in Melanoma; Carlino M, Rizos H; Pfizer Australia Pty Ltd/Research Fellowships.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Gowrishankar, K., Carlino, M., Rizos, H. (2013). Acquired Resistance to Targeted MAPK Inhibition in Melanoma. In Guy Huynh Thien Duc (Eds.), Melanoma - From Early Detection to Treatment, (pp. 197-218). Croatia: InTech Publishers. [More Information]

Journals

  • Eggermont, A., Blank, C., Mandala, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M., Long, G., et al (2018). Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 378(19), 1789-1801. [More Information]
  • Lee, J., Long, G., Menzies, A., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R., Rizos, H., Carlino, M. (2018). Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncology, 4(5), 717-721. [More Information]
  • McQuade, J., Daniel, C., Hess, K., Mak, C., Wang, D., Rai, R., Park, J., Haydu, L., Spencer, C., Wongchenko, M., Carlino, M., Long, G., Menzies, A., et al (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet Oncology, 19(3), 310-322. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Corrigendum to Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]". European Journal of Cancer, 93, 158. [More Information]
  • Eroglu, Z., Zaretsky, J., Hu-Lieskovan, S., Kim, D., Algazi, A., Johnson, D., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Carlino, M., Scolyer, R., Long, G., et al (2018). High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 553(7688), 347-350. [More Information]
  • Palmieri, D., Carlino, M. (2018). Immune Checkpoint Inhibitor Toxicity. Current Oncology Reports, 20(9), 1-12. [More Information]
  • Zhao, C., Hwang, S., Anforth, R., Carlos, G., Chou, S., Carlino, M., Fernandez Penas, P. (2018). Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 41(7), 343-349. [More Information]
  • Lee, J., Lyle, M., Menzies, A., Chan, M., Lo, S., Clements, A., Carlino, M., Kefford, R., Long, G. (2018). Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research, 31(3), 404-410. [More Information]
  • Carlino, M., Long, G., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C., et al (2018). Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. European Journal of Cancer, 101(September 2018), 236-243. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. [More Information]
  • Tio, M., Wang, X., Carlino, M., Shivalingam, B., Fogarty, G., Guminski, A., Lo, S., Hong, A., Menzies, A., Long, G. (2018). Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(4), 509-515. [More Information]
  • Hwang, S., Wakade, D., Kong, B., Carlino, M., Chou, S., Fernandez Penas, P. (2017). Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. Case Reports in Medicine, 2017, 1-3. [More Information]
  • Menzies, A., Johnson, D., Ramanujam, S., Atkinson, V., Wong, A., Park, J., McQuade, J., Shoushtari, A., Tsai, K., Eroglu, Z., Guminski, A., Carlino, M., Long, G., et al (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28(2), 368-376. [More Information]
  • Lee, J., Long, G., Boyd, S., Lo, S., Menzies, A., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R., Mann, G., Kefford, R., Carlino, M., Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130-1136. [More Information]
  • Pupo, G., Boyd, S., Fung, C., Carlino, M., Menzies, A., Pedersen, B., Johansson, P., Hayward, N., Kefford, R., Scolyer, R., Long, G., Rizos, H. (2017). Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 5(17), 1-4. [More Information]
  • Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
  • Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Guminski, A., Kefford, R., Long, G., Menzies, A., Carlino, M., et al (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 116(12), 1558-1563. [More Information]
  • Lim, S., Lee, J., Welsh, S., Ahn, S., Breen, E., Khan, A., Carlino, M., Menzies, A., Kefford, R., Scolyer, R., Long, G., et al (2017). Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 5, 1-12. [More Information]
  • Kakavand, H., Jackett, L., Menzies, A., Gide, T., Carlino, M., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2017). Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 30(12), 1666-1676. [More Information]
  • Wolchok, J., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J., Cowey, C., Lao, C., Wagstaff, J., Schadendorf, D., Carlino, M., Long, G., et al (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377(14), 1345-1356. [More Information]
  • Kakavand, H., Rawson, R., Pupo, G., Yang, J., Menzies, A., Carlino, M., Kefford, R., Howle, J., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R., et al (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research, 23(20), 6054-6061. [More Information]
  • Schachter, J., Ribas, A., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, 390(10105), 1853-1862. [More Information]
  • Park, J., Boddy, A., Liu, X., Harris, D., Lee, V., Kefford, R., Carlino, M. (2017). Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell & Melanoma Research, 30(1), 68-71. [More Information]
  • Delord, J., Robert, C., Nyakas, M., McArthur, G., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R., Carlino, M., et al (2017). Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clinical Cancer Research, 23(18), 5339-5348. [More Information]
  • Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
  • Sidhu, P., Menzies, A., Long, G., Carlino, M., Lorens, S., Kapoor, R. (2017). Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology, 61(6), 759-766. [More Information]
  • Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Guminski, A., Long, G., Carlino, M., et al (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British Journal of Cancer, 116(8), 1-1. [More Information]
  • Carlino, M., Sandhu, S. (2017). Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. American Journal of Clinical Oncology, 35(34), 3792-3793. [More Information]
  • Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]
  • Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
  • Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., et al (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 5(3), 1-8. [More Information]
  • Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., Harnett, P. (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 5(3), 1-8. [More Information]
  • Kong, B., Micklethwaite, K., Swaminathan, S., Kefford, R., Carlino, M. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 26(2), 202-204. [More Information]
  • Hwang, S., Carlos Minano, G., Chou, S., Wakade, D., Carlino, M., Fernandez Penas, P. (2016). Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Research, 26(4), 413-416. [More Information]
  • Carlino, M., Vanella, V., Girgis, C., Giannarelli, D., Guminski, A., Festino, L., Kefford, R., Menzies, A., Long, G., Ascierto, P. (2016). Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series. British Journal of Cancer, 115(11), 1280-1284. [More Information]
  • Hwang, S., Carlos Minano, G., Wakade, D., Byth Wilson, K., Kong, B., Chou, S., Carlino, M., Kefford, R., Fernandez Penas, P. (2016). Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Journal Of The American Academy Of Dermatology, 74(3), 455-461. [More Information]
  • Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Long, G., Carlino, M., et al (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 114(10), 1084-1089. [More Information]
  • Carlino, M., Long, G. (2016). Ipilimumab combined with nivolumab: A standard of care for the treatment of advanced melanoma? Clinical Cancer Research, 22(16), 3992-3998. [More Information]
  • Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
  • Atkinson, V., Long, G., Menzies, A., McArthur, G., Carlino, M., Millward, M., Roberts-Thomson, R., Brady, B., Kefford, R., Haydon, A., et al (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 12(Suppl. 7), 5-12. [More Information]
  • Lee, J., Kefford, R., Carlino, M. (2016). PD-1 and PD-L1 inhibitors in melanoma treatment: Past success, present application and future challenges. Immunotherapy, 8(6), 733-746. [More Information]
  • Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]
  • Chan, M., Kefford, R., Carlino, M., Clements, A., Manolios, N. (2015). Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy, 38(1), 37-39. [More Information]
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Long, G., Carlino, M., et al (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Cowey, C., Lao, C., Schadendorf, D., Dummer, R., Smylie, M., Carlino, M., Long, G., et al (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373(1), 23-34. [More Information]
  • Carlos Minano, G., Anforth, R., Clements, A., Menzies, A., Carlino, M., Chou, S., Fernandez Penas, P. (2015). Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 151(10), 1103-1109. [More Information]
  • Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
  • Lam, T., Chan, M., Sweeting, A., De Sousa, S., Clements, A., Carlino, M., Long, G., Tonks, K., Chua, E., Kefford, R., Chipps, D. (2015). Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. Internal Medicine Journal, 45(10), 1066-1073. [More Information]
  • Long, G., Carlino, M. (2015). Is chemotherapy still an option in the treatment of melanoma? Annals of Oncology, 26(11), 2203-2204. [More Information]
  • Amaravadi, R., Hamilton, K., Ma, X., Piao, S., Del Portillo, A., Nathanson, K., Carlino, M., Long, G., Puzanov, I., Xu, X., et al (2015). Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clinical Cancer Research, 21(23), 5215-5221. [More Information]
  • Carlino, M., Kwan, V., Miller, D., Saunders, C., Yip, D., Nagrial, A., Tomlinson, J., Grimmond, S., Scolyer, R., Kefford, R., Long, G., et al (2015). New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 33(11), e52-E56. [More Information]
  • Robert, C., Schachter, J., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521-2532. [More Information]
  • Carlino, M., Fung, C., Shahheydari, H., Todd, J., Boyd, S., Irvine, M., Nagrial, A., Scolyer, R., Kefford, R., Long, G., Rizos, H. (2015). Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98-105. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
  • Carlino, M., Long, G., Kefford, R., Rizos, H. (2015). Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Critical Reviews in Oncology / Hematology (online), 96(3), 385-398. [More Information]
  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]
  • Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PloS One, 9(1), 1-9. [More Information]
  • Carlino, M., Saunders, C., Haydu, L., Menzies, A., Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013). 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 49(2), 395-402. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]
  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]
  • Carlino, M., Fogarty, G., Long, G. (2012). Treatment of Melanoma Brain Metastases: A New Paradigm. The Cancer Journal, 18(2), 208-212. [More Information]

2018

  • Eggermont, A., Blank, C., Mandala, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M., Long, G., et al (2018). Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 378(19), 1789-1801. [More Information]
  • Lee, J., Long, G., Menzies, A., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R., Rizos, H., Carlino, M. (2018). Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncology, 4(5), 717-721. [More Information]
  • McQuade, J., Daniel, C., Hess, K., Mak, C., Wang, D., Rai, R., Park, J., Haydu, L., Spencer, C., Wongchenko, M., Carlino, M., Long, G., Menzies, A., et al (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet Oncology, 19(3), 310-322. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Corrigendum to Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]". European Journal of Cancer, 93, 158. [More Information]
  • Eroglu, Z., Zaretsky, J., Hu-Lieskovan, S., Kim, D., Algazi, A., Johnson, D., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Carlino, M., Scolyer, R., Long, G., et al (2018). High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 553(7688), 347-350. [More Information]
  • Palmieri, D., Carlino, M. (2018). Immune Checkpoint Inhibitor Toxicity. Current Oncology Reports, 20(9), 1-12. [More Information]
  • Zhao, C., Hwang, S., Anforth, R., Carlos, G., Chou, S., Carlino, M., Fernandez Penas, P. (2018). Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 41(7), 343-349. [More Information]
  • Lee, J., Lyle, M., Menzies, A., Chan, M., Lo, S., Clements, A., Carlino, M., Kefford, R., Long, G. (2018). Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research, 31(3), 404-410. [More Information]
  • Carlino, M., Long, G., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C., et al (2018). Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. European Journal of Cancer, 101(September 2018), 236-243. [More Information]
  • Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. [More Information]
  • Tio, M., Wang, X., Carlino, M., Shivalingam, B., Fogarty, G., Guminski, A., Lo, S., Hong, A., Menzies, A., Long, G. (2018). Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(4), 509-515. [More Information]

2017

  • Hwang, S., Wakade, D., Kong, B., Carlino, M., Chou, S., Fernandez Penas, P. (2017). Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. Case Reports in Medicine, 2017, 1-3. [More Information]
  • Menzies, A., Johnson, D., Ramanujam, S., Atkinson, V., Wong, A., Park, J., McQuade, J., Shoushtari, A., Tsai, K., Eroglu, Z., Guminski, A., Carlino, M., Long, G., et al (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28(2), 368-376. [More Information]
  • Lee, J., Long, G., Boyd, S., Lo, S., Menzies, A., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R., Mann, G., Kefford, R., Carlino, M., Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130-1136. [More Information]
  • Pupo, G., Boyd, S., Fung, C., Carlino, M., Menzies, A., Pedersen, B., Johansson, P., Hayward, N., Kefford, R., Scolyer, R., Long, G., Rizos, H. (2017). Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 5(17), 1-4. [More Information]
  • Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
  • Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Guminski, A., Kefford, R., Long, G., Menzies, A., Carlino, M., et al (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 116(12), 1558-1563. [More Information]
  • Lim, S., Lee, J., Welsh, S., Ahn, S., Breen, E., Khan, A., Carlino, M., Menzies, A., Kefford, R., Scolyer, R., Long, G., et al (2017). Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 5, 1-12. [More Information]
  • Kakavand, H., Jackett, L., Menzies, A., Gide, T., Carlino, M., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2017). Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 30(12), 1666-1676. [More Information]
  • Wolchok, J., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J., Cowey, C., Lao, C., Wagstaff, J., Schadendorf, D., Carlino, M., Long, G., et al (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377(14), 1345-1356. [More Information]
  • Kakavand, H., Rawson, R., Pupo, G., Yang, J., Menzies, A., Carlino, M., Kefford, R., Howle, J., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R., et al (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research, 23(20), 6054-6061. [More Information]
  • Schachter, J., Ribas, A., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, 390(10105), 1853-1862. [More Information]
  • Park, J., Boddy, A., Liu, X., Harris, D., Lee, V., Kefford, R., Carlino, M. (2017). Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell & Melanoma Research, 30(1), 68-71. [More Information]
  • Delord, J., Robert, C., Nyakas, M., McArthur, G., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R., Carlino, M., et al (2017). Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clinical Cancer Research, 23(18), 5339-5348. [More Information]
  • Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
  • Sidhu, P., Menzies, A., Long, G., Carlino, M., Lorens, S., Kapoor, R. (2017). Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology, 61(6), 759-766. [More Information]
  • Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Guminski, A., Long, G., Carlino, M., et al (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British Journal of Cancer, 116(8), 1-1. [More Information]
  • Carlino, M., Sandhu, S. (2017). Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. American Journal of Clinical Oncology, 35(34), 3792-3793. [More Information]
  • Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]

2016

  • Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
  • Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., et al (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 5(3), 1-8. [More Information]
  • Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., Harnett, P. (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. JMIR Research Protocols, 5(3), 1-8. [More Information]
  • Kong, B., Micklethwaite, K., Swaminathan, S., Kefford, R., Carlino, M. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 26(2), 202-204. [More Information]
  • Hwang, S., Carlos Minano, G., Chou, S., Wakade, D., Carlino, M., Fernandez Penas, P. (2016). Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Research, 26(4), 413-416. [More Information]
  • Carlino, M., Vanella, V., Girgis, C., Giannarelli, D., Guminski, A., Festino, L., Kefford, R., Menzies, A., Long, G., Ascierto, P. (2016). Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series. British Journal of Cancer, 115(11), 1280-1284. [More Information]
  • Hwang, S., Carlos Minano, G., Wakade, D., Byth Wilson, K., Kong, B., Chou, S., Carlino, M., Kefford, R., Fernandez Penas, P. (2016). Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Journal Of The American Academy Of Dermatology, 74(3), 455-461. [More Information]
  • Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Long, G., Carlino, M., et al (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 114(10), 1084-1089. [More Information]
  • Carlino, M., Long, G. (2016). Ipilimumab combined with nivolumab: A standard of care for the treatment of advanced melanoma? Clinical Cancer Research, 22(16), 3992-3998. [More Information]
  • Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
  • Atkinson, V., Long, G., Menzies, A., McArthur, G., Carlino, M., Millward, M., Roberts-Thomson, R., Brady, B., Kefford, R., Haydon, A., et al (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 12(Suppl. 7), 5-12. [More Information]
  • Lee, J., Kefford, R., Carlino, M. (2016). PD-1 and PD-L1 inhibitors in melanoma treatment: Past success, present application and future challenges. Immunotherapy, 8(6), 733-746. [More Information]
  • Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]

2015

  • Chan, M., Kefford, R., Carlino, M., Clements, A., Manolios, N. (2015). Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy, 38(1), 37-39. [More Information]
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Long, G., Carlino, M., et al (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Cowey, C., Lao, C., Schadendorf, D., Dummer, R., Smylie, M., Carlino, M., Long, G., et al (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373(1), 23-34. [More Information]
  • Carlos Minano, G., Anforth, R., Clements, A., Menzies, A., Carlino, M., Chou, S., Fernandez Penas, P. (2015). Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 151(10), 1103-1109. [More Information]
  • Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
  • Lam, T., Chan, M., Sweeting, A., De Sousa, S., Clements, A., Carlino, M., Long, G., Tonks, K., Chua, E., Kefford, R., Chipps, D. (2015). Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. Internal Medicine Journal, 45(10), 1066-1073. [More Information]
  • Long, G., Carlino, M. (2015). Is chemotherapy still an option in the treatment of melanoma? Annals of Oncology, 26(11), 2203-2204. [More Information]
  • Amaravadi, R., Hamilton, K., Ma, X., Piao, S., Del Portillo, A., Nathanson, K., Carlino, M., Long, G., Puzanov, I., Xu, X., et al (2015). Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clinical Cancer Research, 21(23), 5215-5221. [More Information]
  • Carlino, M., Kwan, V., Miller, D., Saunders, C., Yip, D., Nagrial, A., Tomlinson, J., Grimmond, S., Scolyer, R., Kefford, R., Long, G., et al (2015). New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 33(11), e52-E56. [More Information]
  • Robert, C., Schachter, J., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521-2532. [More Information]
  • Carlino, M., Fung, C., Shahheydari, H., Todd, J., Boyd, S., Irvine, M., Nagrial, A., Scolyer, R., Kefford, R., Long, G., Rizos, H. (2015). Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98-105. [More Information]
  • Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
  • Carlino, M., Long, G., Kefford, R., Rizos, H. (2015). Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Critical Reviews in Oncology / Hematology (online), 96(3), 385-398. [More Information]

2014

  • Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
  • Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
  • Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
  • Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]
  • Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PloS One, 9(1), 1-9. [More Information]

2013

  • Carlino, M., Saunders, C., Haydu, L., Menzies, A., Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013). 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 49(2), 395-402. [More Information]
  • Gowrishankar, K., Carlino, M., Rizos, H. (2013). Acquired Resistance to Targeted MAPK Inhibition in Melanoma. In Guy Huynh Thien Duc (Eds.), Melanoma - From Early Detection to Treatment, (pp. 197-218). Croatia: InTech Publishers. [More Information]
  • Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]

2012

  • Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]
  • Carlino, M., Fogarty, G., Long, G. (2012). Treatment of Melanoma Brain Metastases: A New Paradigm. The Cancer Journal, 18(2), 208-212. [More Information]

To update your profile click here. For support on your academic profile contact .